MAZE THERAPEUTICS, INC. (MAZE) Pre-Tax Margin
- 2024-09-30: Pre-Tax Margin -1001.24%.
- 2024-06-30: Pre-Tax Margin 85.32%.
Complete source-backed pre-tax margin history.
- Available history
- 2024-06-30 to 2024-12-31
- Data captured
Historical Pre-Tax Margin
| Date | Pre-Tax Margin |
|---|---|
| 2024-09-30 | -1001.24% |
| 2024-06-30 | 85.32% |
Annual Pre-Tax Margin
| Date | Pre-Tax Margin |
|---|---|
| 2024-12-31 | 31.88% |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |